Background
A clinical-stage biopharmaceutical company focused on developing precision antibiotics for serious infectious diseases conducting a Phase 2 clinical trial.
The challenge
Partway through the trial, the sponsor faced an urgent supply chain issue: their comparator drug was unexpectedly removed from the market. Without immediate resolution, the study risked halting enrolment and jeopardizing critical regulatory timelines.
“Matrix understood the urgency and clinical context immediately. Their ability to find a compliant alternative and move fast made the difference between a delay and a delivered trial."
The solution
Matrix responded rapidly to the escalation. Our clinical supply specialists identified and validated an equivalent generic product and delivered a continuity strategy that required no protocol amendments, with a direct supply agreement with the MAH. The first supply was delivered to the Sponsor’s packaging site on schedule and in full.
The outcome
Begin your
partnership
with Matrix
